A new plain language summary in Future Oncology describes in detail the INVICTUS study originally published in the journal Lancet Oncology. The INVICTUS study looked at ripretinib as a potential treatment for advanced gastrointestinal stromal tumor.
Read the full article here.
The original article, called ‘Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial’ was published in Lancet Oncology and can be read here.